


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院

Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Sto

Upon the appointment of the above candidates for Directors at the AGM, a service contract will be entered into between each of the candidates for Directors and the Company. During their term of office, Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian will receive remuneration as Directors after being elected in accordance with the Company's remuneration management measures, which primarily consists of basic salary, performance-based compensation and welfare benefits. Performance-based compensation is primarily determined based on the Group's operating results and individual performance. The Company will disclose the remuneration amounts once finalized. For details of remuneration, please refer to the annual report to be published by the Company in due course; Mr. QIN Hao and Mr. LI Changhao will not receive any remuneration from the Company in their capacity as non-executive Directors after being elected; the Directors' fee of Ms. ZHONG Wentang, Ms. JIN Ling and Mr. SZETO Wing Fu after being elected shall be determined based on the recommendation of the Remuneration Committee of the Company after taking into full account of factors such as the remuneration level of independent non-executive directors in the PRC companies with the scale and nature of business similar to those of the Company. The Company will disclose the remuneration amounts once finalized. For details, please refer to the annual report to be published by the Company in due course.

The biographical details of the candidates for Directors of the fifth session of the Board are set out in Appendix I to this announcement.

Save as disclosed in Appendix I, the above candidates for Directors have not held any other directorships over the past three years in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas, did not hold any other major appointments and professional qualifications, nor have they held any position in the Company or its subsidiaries, nor do they have any relationship with any other Directors, supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company. As at the date of this announcement, save as disclosed in Appendix I, they have no interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The above candidates for Directors have not been subject to any penalties imposed by the China Securities Regulatory Commission or other relevant securities regulatory authorities or any stock exchanges.

In addition, save as disclosed in Appendix I, none of the above candidates for Directors has any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities (the “Rules Governing the Listing of Securities”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and they are not/were not involved in any of the matters required to be disclosed pursuant to the aforesaid requirements. Save as stated in Appendix I, there are no other matters that need to be brought to the attention of the Shareholders.

Mr. CHAN Sai Keung Hugo, the existing independent non-executive Director, will retire upon the expiration of his term of office as Director, with effect from the date on which the Directors of the fifth session of the Board officially assume their duties. Until then, Mr. CHAN Sai Keung Hugo will continue to perform his duties as a Director. Mr. CHAN Sai Keung Hugo has confirmed that he has no disagreement with the Company or the Board and there are no other matters relating to his retirement that need to be brought to the attention of the Shareholders of the Company and the Stock Exchange. The Board would like to take this opportunity to express its sincere gratitude to Mr. CHAN Sai Keung Hugo for his valuable contribution to the Company during his tenure of office.

The term of the fourth session of the supervisory committee (the “第四届监事会”) of the Company is due to expire. In order to ensure the smooth election and smooth implementation of the work, the Supervisory Committee agreed to nominate three candidates for supervisors (the “第三届监事”) to the Supervisory Committee, including two Shareholder representative Supervisors and one independent Supervisor. Pursuant to the Articles, the employee representative Supervisors shall account for not less than one-third of the Supervisors in the Supervisory Committee and shall be elected and dismissed at the employees’ representative meeting by the employees of the Company or through other democratic procedures. The Company will convene an employees’ representative meeting to elect employee representative Supervisor(s) and will duly publish an announcement for this meeting.

The following is the list of candidates for the Shareholder representative Supervisors and independent Supervisor of the fifth session of the Supervisory Committee, which has been considered and approved by the Supervisory Committee:

- (1) candidates for Shareholder representative Supervisors: Mr. XU Yongjiu and Mr. FANG Wei;
and
- (2) candidate for independent Supervisor: Mr. QIAN Chengliang.

The above candidates for Supervisors meet the requirements as stipulated in relevant PRC laws and regulations and the Articles, and the Supervisory Committee agreed to propose ordinary resolutions in respect of the above list of candidates at the AGM for consideration.

The Supervisors of the fifth session of the Supervisory Committee will serve for a term of three years, and the term of office of these Shareholder representative Supervisors and independent Supervisor will take effect from the date of approval at the AGM until the expiration of the term of office of the fifth session of the Supervisory Committee, and they shall be eligible for re-election upon expiry of the term.

Upon the appointment of the above candidates for Supervisors at the AGM, a service contract will be entered into between each of the candidates for Supervisors and the Company. During the term of office, the Shareholder representative Supervisors and the independent Supervisor will not receive any remuneration or allowance from the Company.

The biographical details of the candidates for the Shareholder representative Supervisors and independent Supervisor of the fifth session of the Supervisory Committee are set out in Appendix II to this announcement.

Save as disclosed in Appendix II, the above candidates for Supervisors have not held any other directorships over the past three years in any public companies, the securities of which are listed on any securities market in Hong Kong and/or overseas, did not hold any other major appointments and professional qualifications, nor have they held any position in the Company or its subsidiaries, nor do they have any relationship with any other Directors, Supervisors, senior management, substantial or controlling Shareholders of the Company. As at the date of this announcement, save as disclosed in Appendix II, they have no interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The above candidates for Supervisors have not been subject to any penalties imposed by the China Securities Regulatory Commission or other relevant securities regulatory authorities or any stock exchanges.

In addition, save as disclosed in Appendix II, none of the above candidates for Supervisors has any information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and they are not/were not involved in any of the matters required to be disclosed pursuant to the aforesaid requirements. Save as disclosed above, there are no other matters that need to be brought to the attention of the Shareholders.

The Company will convene the AGM to approve the appointment of the Directors and Supervisors. A circular and notice containing, among others, details of the Directors and Supervisors proposed to be appointed is expected to be dispatched to the Shareholders as soon as reasonably practicable in accordance with the manner in which the Shareholders have chosen to receive corporate communications.

By order of the Board


Chairman

Zhejiang, the PRC
April 29, 2026

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.

A. B. A. A. T. T. T. T.

Mr. GUAN Weili (管偉立), aged 56, is the chairman of the Board and an executive Director of the Company. He is primarily responsible for the overall business operation and strategic planning of the Company. He founded the Company in February 1996 and became an executive Director since then. Mr. GUAN was appointed as the chairman of the Board and an executive Director in September 2014 after the Company was converted into a joint stock limited liability company. Prior to joining the Company, Mr. GUAN served as a clinician at Wenzhou Mental Hospital (溫州市精神病院), a local hospital in Wenzhou, from August 1987 to December 1993, where he was primarily responsible for the medical treatment of psychiatric patients.

Mr. GUAN graduated from Wenzhou Medical University (溫州醫科大學) (previously known as Wenzhou Medical College (溫州醫學院)) in Wenzhou in August 1987, majoring in medical assistance. Mr. GUAN obtained his senior business operator certificate from Wenzhou Municipal Bureau of Personnel (溫州市人事局) in December 2007. Mr. GUAN is the spouse of Ms. WANG Lianyue and the brother-in-law of Mr. XU Yi (vice general manager of the Company).

As at the date of this announcement, Mr. GUAN is deemed to be interested in 27,330,100 domestic shares of the Company and 458,300 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), of which 18,350,250 domestic shares of the Company are beneficially owned, 3,194,500 domestic shares of the Company and 149,300 H shares of the Company are held as interest of spouse, and 5,785,350 domestic shares of the Company and 309,000 H shares of the Company are held jointly with another person.

Ms. WANG Lianyue (王蓮月), aged 57, is an executive Director and the general manager of the Company. She is primarily responsible for the overall hospital operation and business development of the Company. She joined the Company in January 1998 and has served as our general manager since September 2011 and our executive Director since April 2013. Ms. WANG was appointed as our executive Director again in September 2014 after the Company was converted into a joint stock limited liability company. Prior to joining the Company, from August 1988 to December 1997, she was a nurse at Wenzhou Mental Hospital (溫州市精神病院), where she was primarily responsible for general patient care.

Ms. WANG received two associate degrees from Wenzhou Medical University (溫州醫科大學) (previously known as Wenzhou Medical College (溫州醫學院)) in Wenzhou in June 2004 and the Party School of Wenzhou Municipal Committee of the Communist Party of China (中共溫州市委黨校) in Wenzhou in June 2002, where she majored in nursing and economic administration respectively. She graduated from Online Education College of Xi'an Jiaotong University (西安交通大學網絡教育學院), through long-distance education, with a bachelor's degree in law in July 2007. She also completed part-time hospital management courses at the China Europe International Business School (中歐國際工商學院) in Shanghai in September 2006. She was accredited as secondary psychological consultant (二級心理諮詢師) by the Ministry of Human Resources and Social Security of China (人力資源和社會保障部) in December 2004. Ms. WANG is the spouse of Mr. GUAN Weili and the sister-in-law of Mr. XU Yi (vice general manager of the Company).

As at the date of this announcement, Ms. WANG is deemed to be interested in 27,330,100 domestic shares of the Company and 458,300 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), of which 3,194,500 domestic shares of the Company and 149,300 H shares of the Company are beneficially owned, 18,350,250 domestic shares of the Company are held as interest of spouse, and 5,785,350 domestic shares of the Company and 309,000 H shares of the Company are held jointly with another person.

王健 (王健), aged 41, is an executive Director, the vice general manager and the secretary to the Board of the Company. He is primarily responsible for overseeing public affairs and investment relationship, corporate financing and listing-related matters. Mr. WANG Jian joined the Company in July 2014 and has served as the secretary to the Board of the Company since then. Mr. WANG Jian was appointed as the secretary to the Board of the Company again in September 2014 after the Company was converted into a joint stock limited liability company. He was appointed as an executive Director and the executive vice general manager of the Company in June 2023. Prior to joining the Company, from June 2009 to July 2014, he served as a staff member (科員) and a senior staff member (副主任科員) in the Xiamen Regulatory Bureau of China Securities Regulatory Commission (中國證券監督管理委員會廈門監管局) where he was primarily responsible for monitoring the corporate governance and information disclosure of listed companies in the Xiamen area. From February 2008 to March 2009, he was a senior auditor at Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)), where he was primarily responsible for audit work. From August 2005 to February 2008, he served as an auditor and senior auditor at PricewaterhouseCoopers Zhongtian Certified Public Accountants Limited, mainly responsible for audit work.

Mr. WANG Jian obtained a bachelor's degree in management from Guanghai School of Management at Peking University (北京大學光華管理學院) in Beijing in July 2005, where he majored in business administration. Mr. WANG Jian was recognized as a non-practicing certified public accountant (註冊會計師非執業會員) by the Chinese Institute of Certified Public Accountants in April 2010 and was granted the legal professional qualification certificate by the Ministry of Justice of the PRC in March 2014.

As at the date of this announcement, Mr. WANG is deemed to be beneficially interested in 100,000 domestic shares of the Company and 209,100 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

秦浩 (秦浩), aged 35, is a non-executive Director of the Company and joined the Group in June 2021. Since January 2022, he has served as a vice president of investment of Shanghai Loyal Valley Investment Management Co., Limited (上海正心谷投資管理有限公司), a private equity investment company that mainly invests in the fields of new consumption, healthcare and advanced manufacturing, where he is mainly responsible for the investment in pharmaceutical and healthcare industry. He served as a senior investment manager of Shanghai Loyal Valley Investment Management Co., Limited from June 2017 to December 2021.

秦浩 (秦浩), aged 35, is a non-executive Director of the Company and joined the Group in June 2021. Since January 2022, he has served as a vice president of investment of Shanghai Loyal Valley Investment Management Co., Limited (上海正心谷投資管理有限公司), a private equity investment company that mainly invests in the fields of new consumption, healthcare and advanced manufacturing, where he is mainly responsible for the investment in pharmaceutical and healthcare industry. He served as a senior investment manager of Shanghai Loyal Valley Investment Management Co., Limited from June 2017 to December 2021.

Mr. QIN graduated from Peking University in June 2014 with a bachelor's degree in medicine. He graduated from Fudan University in June 2017 with a master's degree in finance.

李昌浩 (李昌浩), aged 36, is a non-executive Director of the Company and joined the Group in October 2021. Since January 2022, he has served as the executive deputy general manager of the resource development team of SDIC Chuangyi Industry Fund Management Co., Ltd. (國投創益產業基金管理有限公司), mainly responsible for the investment in private equity projects. Since May 2019, Mr. LI has served as a director of CTS Guangxi Detian Waterfall Tourism Development Co., Ltd. (中旅廣西德天瀑布旅遊開發有限公司), a company engaged in the development of tourist attractions. From May 2014 to December 2021, Mr. LI consecutively served as the investment manager and the vice president of SDIC Chuangyi Industry Fund Management Co., Ltd. From October 2023 to November 2025, he has served as a supervisor of Ningxia Yinxing Energy Co., Ltd. (寧夏銀星能源股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000862) engaged in new energy power generation and new energy equipment engineering businesses.

Mr. LI graduated from Beijing University of Posts and Telecommunications with a bachelor's degree in e-commerce and law in September 2012. He graduated from Queen Mary University of London with a master's degree in marketing in December 2013. Mr. LI was accredited as a chartered financial analyst (CFA) by the Chartered Financial Analyst Institute in August 2017, an intermediate analyst by the Ministry of Human Resources and Social Security of the People's Republic of China in December 2017, and a certified financial risk manager (FRM) by the Global Association Risk Professionals in August 2018.

鐘文堂 (鐘文堂), aged 36, is an independent non-executive Director of the Company and joined the Group in June 2020. Since February 2019, Ms. ZHONG has served as a partner at Shanghai Infaith Consulting Co., Ltd. (上海信公企業管理諮詢有限公司), a company engaged in providing consultation services for listed companies, where she is mainly responsible for business in sustainable development and in charge of marketing and sales. From February 2016 to February 2019, she served as a senior consultation manager and consultation business director successively in Shanghai Infaith Consulting Co., Ltd., mainly responsible for business in compliance consultation. From October 2012 to February 2016, she served as an auditor and senior auditor successively in PricewaterhouseCoopers Zhong Tian CPAs Limited Company, mainly responsible for finance and audit for internal control.

Ms. ZHONG graduated from Fudan University in Shanghai with a bachelor's degree in sociology in June 2012. She obtained her degree in Master of Business Administration from Fudan University in June 2022.

金玲 (金玲), aged 67, is an independent non-executive Director of the Company and joined the Group in June 2023. Ms. JIN has been the adviser to president and the Chief Accountant of Xiaoshan First People's Hospital (蕭山第一人民醫院) since June 2022. Ms. JIN served as the Chief Accountant of People's Hospital of Zhejiang Province (浙江省人民醫院) from May 2000 to December 2008; the Chief Accountant of the Affiliated Children's Hospital of Zhejiang University School of Medicine (浙江大學醫學院附屬兒童醫院) from January 2009 to June 2013; the Chief Accountant of the Second Affiliated Hospital of Zhejiang University School of Medicine (浙江大學醫學院附屬第二醫院) from July 2013 to December 2018; and the Chief Financial Officer of Shulan (Hangzhou) Hospital (樹蘭(杭州)醫院) from January 2019 to May 2022. Ms. JIN was once engaged concurrently as a lecturer at the Beijing National Accounting Institute (北京國家會計學院) and Zhejiang University School of Management (浙江大學管理學院).

Ms. JIN graduated from Hangzhou Institute of Electronic Engineering (杭州電子工業學院) with an adult undergraduate degree in July 1996; she obtained a master's degree in business administration from The Open University of Hong Kong (now known as Hong Kong Metropolitan University) in June 2005. In December 2010, Ms. JIN was accredited as a senior accountant by the Human Resources and Social Security Department of Zhejiang Province (浙江省人力資源和社會保障廳).

司徒永富 (司徒永富), aged 64. Since October 1999, Mr. SZETO Wing Fu has served as the chief executive officer and an executive director of Hung Fook Tong Group Holdings Limited, a company listed on the Hong Kong Stock Exchange (stock code: 01446) principally engaged in the production and sales of Chinese herbal drinks and other drink products. He is also a member of the nomination committee and the chairman of the strategy and development committee of the company. During the same period, he has served as a director of various subsidiaries of Hung Fook Tong Group, where he is fully responsible for the day-to-day operations and management of the group, recommending strategies to the board of directors, and setting and implementing corporate and operational decisions. From August 1987 to August 1992, he served as a deputy manager at Ka Wah Bank Limited. He served as an associate professor of the Department of Business Administration of Shue Yan University for over 15 years and is currently a professor of practice (finance) of the School of Accounting and Finance at The Hong Kong Polytechnic University. He currently serves as a non-official member of the Minimum Wage Commission of Hong Kong, a member of the Executive Committee of the Hong Kong Retail Management Association, the chairman of the Hospital Governing Committee of MacLehose Medical Rehabilitation Centre in Hong Kong, the vice-chairperson of the Executive Committee, the chairperson of Long Term Care Committee, and a member of the Fundraising and Social Enterprise Committee of The Hong Kong Society for Rehabilitation.

Mr. SZETO graduated from Hong Kong Shue Yan College with a diploma in economics in July 1984. He graduated from University of Southern Mississippi with a doctor of philosophy in education administration in May 1995. Mr. SZETO was certified as a fellow certified public accountant of CPA Australia (FCPA (Aust.)). Mr. SZETO was awarded the "Linchpin of Asia Awards 2023 (Entrepreneur Category)" by Enterprise Asia in 2023.

The above candidates for independent non-executive Directors have confirmed that they have all the elements of independence set out in Rule 3.13 of the Listing Rules. Specifically, each of the candidates for independent non-executive Directors has confirmed that he/she:

- (i) meets the independence criteria relating to each of the factors set out in Rules 3.13(1) to (8) of the Listing Rules;
- (ii) does not have any past or present financial or other interest in the business of the Company or any of its subsidiaries, nor does he/she have any connection with any core connected person (as defined under the Listing Rules) of the Company; and
- (iii) is not aware of any other factors that may affect his/her independence at the time of nomination.

The Company considers the above candidates for independent non-executive Directors to be independent in accordance with the guidelines on independence as set out in the Listing Rules. The nomination committee of the Board has assessed and reviewed the independence of each of the candidates for independent non-executive Directors and believes that they have satisfied the requirements for independence.

The nomination of the above candidates for independent non-executive Directors was proposed by the Board, preliminarily reviewed by the nomination committee of the Board, considered by the Board, and will be submitted to the AGM for consideration, in accordance with the provisions of the Articles. The above candidates for independent non-executive Directors possess professional knowledge in financial management, auditing, internal control and risk management, and laws as well as other requisite work experience to perform the duties of an independent non-executive Director. They possess fundamental knowledge of the operation of listed companies and are acquainted with relevant laws, administrative regulations, rules, and other regulatory documents. The nomination committee of the Board is of the view that the above candidates for independent non-executive Directors will properly discharge their duties and responsibilities as independent non-executive Directors and will, through their extensive experience and knowledge, offer objective, independent and sufficient opinions and analysis in respect of compliance, market operation, internal control and auditing and corporate governance, facilitate the scientific and objective decision-making of the Board in terms of corporate governance structure and the protection of the rights and interests of public Shareholders, provide opinions and suggestions on scientific decision-making and risk prevention, and propel the continuous improvement in corporate governance of the Company while promoting diversity of the Board structure, including gender, culture, professional skills and qualifications, etc. None of the above candidates for independent non-executive Directors holds directorships in six or more listed companies, and therefore each of them is able to devote sufficient time and attention to the Company.

As at the date of this announcement, the positions held by the candidates for Directors of the fifth session of the Board in the members of the Group are as follows:

姓名	担任职务	任职时间
GUAN Weili	Cangnan Kangning Hospital Co., Ltd. Yongjia Kangning Hospital Co., Ltd.	Executive director Executive director
	Yongjia Kangning Hospital Co., Ltd.	Director
	Yueqing Kangning Hospital Co., Ltd.	Executive director
	Wenzhou Yining Geriatric Hospital Co., Ltd.	Director
	Pingyang Kangning Hospital Co., Ltd.	Executive director
	Wenzhou Lucheng Yining Hospital Co., Ltd.	Chairman, General manager
	Wenzhou Yining Nursing Home Co., Ltd.	Director
	Qingtian Kangning Property Management Co., Ltd.	Director
	Qingtian Kangning Hospital Co., Ltd.	Director

姓名	单位名称	职务	任职时间
WANG Lianyue	Yiwu Kangning Hospital Management Co., Ltd.	Executive director, Manager	From January 2017 to present
	Qingtian Kangning Hospital Co., Ltd.	Manager	From December 2018 to present
	Hangzhou Yining Nursery Service Co., Ltd.	Executive director, General manager	From December 2020 to present
	Zhejiang Yining Health Technology Co., Ltd.	Executive director	From September 2022 to present
	Zhejiang Dening Pharmaceutical Co., Ltd.	Chairman	From September 2022 to present
	Chun'an Kangning Huangfeng Hospital Co., Ltd.	Director	From November 2022 to present
	Changchun Kanglin Psychological Hospital Co., Ltd.	Chairman	From May 2023 to present
	Wenzhou Gaopin Fangzhou Hospital Co., Ltd.	Chairman, Manager	From November 2025 to present
	Beijing Yining Hospital Co., Ltd.	Executive director	From June 2024 to present
	Qingtian Kangning Property Management Co., Ltd.	Manager	From November 2024 to present
WANG Jian	Quzhou Yining Hospital Co., Ltd.	Director	From November 2015 to present
	Wenling Nanfang Psychiatric Specialty Hospital Co., Ltd.	Chairman, Manager	From January 2019 to present
	Huainan Kangning Hospital Co., Ltd.	Director	From June 2019 to present
	Heze Yining Psychiatric Hospital Co., Ltd.	Director	From July 2019 to present
	Yining Internet Hospital (Wenzhou) Co., Ltd.	Executive director, General manager	From March 2020 to February 2025
	Zhejiang Yining Health Technology Co., Ltd.	Manager	From March 2020 to present
	Wenzhou Lucheng Yining Hospital Co., Ltd.	Director	From April 2020 to present
	Jingyun Shuning Hospital Co., Ltd.	Chairman	From October 2022 to present
	Longquan Kangning Hospital Co., Ltd.	Executive director, General manager	From February 2023 to present
	Beijing Yining Hospital Co., Ltd.	Director, Manager	From February 2023 to present
	Changchun Kanglin Psychological Hospital Co., Ltd.	Director	From May 2023 to present
	Chengdu Jinniu Yining Psychiatric Hospital Co., Ltd.	Chairman	From December 2023 to present
	Zhejiang Yining Geriatric Health (From September 2023 to present)		

A. 董事 - B. 監事

徐永久 (XU Yongjiu), aged 48, is a Supervisor of the Company. He joined the Company in October 2021 and is primarily responsible for supervising our daily operations and management. Since April 2023, Mr. XU has served as a president, director and chairman of the investment committee of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司) and is mainly responsible for the comprehensive operations and management. Since June 2021, he has been the representative appointed by the managing partners of Wenzhou Jinning Equity Investment Partnership (Limited Partnership) (溫州金寧股權投資合夥企業(有限合夥)). From July 2004 to December 2007, he served as the senior investment manager of the Development Research Headquarters of Shanghai International Group. From December 2007 to March 2009, he worked at the Investment Banking Headquarters in Asia Pacific of Citigroup. From March 2009 to September 2011, he served as an executive director of Shanghai International Group and the Securities Investment Headquarters of Shanghai Trust. From October 2011 to October 2015, Mr. XU served as an executive director of GP Capital Co., Ltd. (金浦產業投資基金管理有限公司). From April 2016 to March 2023, he served as a director, member of the investment committee and senior partner of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司) and was mainly responsible for financial and medical investment.

Mr. XU graduated from Southwestern University of Finance and Economics with a bachelor's degree in economics in July 2000. He graduated from Fudan University with a master's degree in finance in June 2004. Since January 2015, he has been studying in the School of Life Sciences at Fudan University, where he receives his master's degree in biotechnology engineering. He graduated from China Europe International Business School with EMBA (Executive Master of Business Administration) in November 2022.

As at the date of this announcement, Mr. XU is deemed to be interested in 4,540,000 domestic shares of the Company held through a controlled corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

方巍先生 (FANG Wei), aged 39, is a Supervisor of the Company. He joined the Company in June 2025 and is currently primarily responsible for overseeing our daily operations and management. Mr. FANG worked in the Digital Marketing Department of Accenture (China) Co., Ltd. from 2010 to 2011. Since 2011, he has been with Shanghai Yuhong Capital Co., Ltd. (上海禹閣投資管理有限公司), a private equity firm specializing in impact investing, where he has served successively as an investment manager, vice president and senior vice president. He is currently an executive director, mainly responsible for investment and post-investment project management in the healthcare and elderly care industry.

Mr. FANG graduated from the University of Nottingham in the United Kingdom with a bachelor's degree in management in 2008. He graduated from the University of Nottingham in the United Kingdom with a master's degree in management psychology in 2009. He obtained his master's degree in business administration from PBC School of Finance of Tsinghua University and a master's degree in business administration from Cornell University in the United States in 2020.

11

錢成良 (錢成良), aged 75, is the independent Supervisor of the Company. He is primarily responsible for monitoring our compliance with laws and regulations. Mr. QIAN joined the Company in June 2017 and has served as our independent Supervisor since then. Prior to joining the Company, from May 2007 to May 2012, he served as a deputy director at the Standing Committee of Wenzhou Municipal People's Congress (溫州市人大常委會). From February 2003 to April 2007, he served as a vice mayor of Wenzhou. From October 1996 to January 2003, he served as the head of the organization division of Standing Committee of the municipal committee of the Communist Party in Lishui (麗水市委常委). From November 1995 to September 1996, he served as an executive deputy head of the organization division of the municipal committee of the Communist Party in Wenzhou.